BR55 in Characterization of Ovarian Lesions

NCT03493464 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision; expiration of available study agent due to long recruitment timeline.

Conditions

Ovarian Cancer

Interventions

DRUG: BR55

Sponsor

Bracco Diagnostics, Inc

Collaborators

[object Object]